O404 Aims: Rejection of islet xenografts is primarily mediated by a cellular immune response and can be modulated by costimulatory blockade. The aim of our study was to evaluate the role of CD40-CD40L pathway in the rejection process of concordant and discordant islet xenografts. Methods: Streptozotocin-induced diabetic C57BL/6, CD40- knockout (KO) or CD40L-KO mice were transplanted under the kidney capsule with either rat islets (300 islets) or human islets (1000 islets). For rat-to-mouse and human to-mouse combination, 4 experimental groups were performed (6 recipients per group): Group 1, islet transplantation (TX) in C57BL/6 mice without further therapy; Group 2, islet TX in C57BL/6 mice with anti-CD154 mAb (MR1) therapy (0.5mg i.p. on days 0, 2 and 4); Group 3, islet TX in CD40-knockout mice and Group 4, islet TX in CD40L-knockout mice. Islet function was measured by glycemia and histology was performed on regular intervals. Results: Short-term MR1 therapy significantly prolonged both concordant (median graft survival (MGS) >120 vs 17 days for controls, p < 0.001) and discordant xenograft survival (MGS >120 vs 11 days for controls, p < 0.005), compared to controls. In CD40-KO mice, concordant xenograft survival was shorter compared to control (MGS 9 versus 17 days, p = 0.5), but discordant xenograft survival was prolonged (MGS 27 versus 11 days, p = 0.06). In CD40L-KO, concordant xenograft survival (MGS 17 versus 17 days) and discordant xenograft survival (MGS 16 versus 11 days) was not significantly modified compared to controls. In Group 1, histology obtained at rejection showed dense graft infiltration by immune cells and IgG, IgM and C3 deposition. In Group 2, histology performed after 120 days showed a mixed cellular infiltrate around intact islets, without antibody or C3 deposition. In Groups 3 and 4, a moderate cellular infiltrate was observed at rejection, with no IgG, but moderate IgM and C3 deposition. Conclusions: Short-term anti-CD154 mAb therapy significantly prolonged rat-to-mouse and human-to-mouse xenograft survival compared to control groups. In CD40 KO and CD154 KO groups, survival of concordant or discordant islets was not prolonged significantly compared to control groups. Improved graft survival among the anti-CD154 mAb treated mice could potentially be explained by specific targeting of activated T cells with subsequent inactivation by anergy and/or elimination by apoptosis, complement- or cellular-mediated mechanisms. Rejection of xenografts in CD40 or CD154 KO animals is possible through the efficient activation of alternate pathways of costimulation.
Read full abstract